Low-vision therapy justified, ophthalmologists claim
13 May 2008

A new report suggests that low-vision therapy programs appear to significantly improve the vision of patients with macular diseases.

Findings published in the latest issue of Archives of Ophthalmology reveal that low-vision therapy, including home visits, counselling, assistive devices such as magnifiers and practice assignments, seem to have a positive effect on chronic visual impairment.

"In most cases, impaired vision cannot be corrected and rehabilitation is the only option for regaining lost function for the patient with low vision. Low-vision rehabilitation aims to restore functional ability, the ability to perform tasks modulated by visual impairment," the report's authors wrote.

According to the experts, impaired vision can increase the risk of depression, injury and have a notable impact on overall health.

The team of researchers in Illinois, concluded: "At least ten hours of low-vision therapy, including a home visit and assigned homework to encourage practice, is justified for patients with moderate and severe vision loss from macular diseases."

Macular degeneration, which affects the central vision, is the most common cause of vision loss among adults above the age of 60 and impacts millions of adults each year.

Register now to access our FREE educational library

Print Article    Bookmark

• Study highlights lack of sleep and exercise as cancer risk 18/11/08
• Doctors warned over pre-eclampsia risk in pregnant women 05/11/08
• Yoghurt found to reduce cancer risk 17/10/08
• Gender link explored in CHD research 14/10/08
• Additional testing may improve breast cancer risk assessment 29/07/08

• TRITACE Tablets - 24.72%
  ... more who have one or more of the following clinical findings: hypertension (systolic blood pressure> 160mmHg or diastolic blood pressure > 90mmHg); high total cholesterol (>5.2 mmol/L); low HDL (<0.9 mmol/L); current smoker; known microalbuminuria; clinical evidence of previous vascular disease ...
  
  
• TRITACE Titration Pack - 24.36%
  ... who have one or more of the following clinical findings: hypertension (systolic blood pressure > 160mmHg or diastolic blood pressure > 90mmHg); high total cholesterol (>5.2 mmol/L); low HDL (<0.9 mmol/L); current smoker; known microalbuminuria; clinical evidence of previous vascular disease. Oral ...
  
  
• BETAFERON - 23.54%
  ... of clinical relapses in ambulatory patients, who have had at least two attacks of neurological dysfunction in the preceding two years followed by complete or incomplete recovery. Secondary progressive multiple sclerosis - Slowing progression of disease and reduction in frequency of clinical relapses ...
  
  
• LOCOID Ointment - 22.5%
  The product is recommended for clinical use in the treatment of conditions responsive to topical corticosteroids e.g. eczema, dermatitis and psoriasis. Topical corticosteroids are not generally indicated in psoriasis but may be acceptable in psoriasis excluding widespread plaque psoriasis provided ...
  
  
• NAGLAZYME Solution for Infusion - 22.5%
  ... it is of primary importance, especially in severe forms, to initiate treatment as early as possible, before appearance of non-reversible clinical manifestations of the disease. A key issue is to treat young patients aged <5 years suffering from a severe form of the disease, even though patients <5 ...
  
  
• ELAPRASE Solution for Infusion - 22.5%
  Elaprase is indicated for the long-term treatment of patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). Heterozygous females were not studied in the clinical trials ...